NorthWest Biotherapeutics Inc (NWBO)

[DocLee]

This is not a dendrocytic therapy but is immunotherapy using checkpoint inhibitors which the patient developed for the treatment of malignant melanoma. A description of this treatment first appeared as an article last December' in the New York Post. The an article on the BBC's website is an update on the Prof Scolyer's progress whilst he is on his self-designed immunotherapeutic treatment for the glioblastoma which he developed last year.

Australia-based Prof. Scolyer is an expert on the immunotherapy of Malignant Melanoma and is currently involved in the NADINA trial [NeoADdjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab] in Macroscopic Stage III Melanoma] with centres in Australia, the USA and Europe. It has nothing to do with brain tumours (unless the melanoma has metastasized to the brain).

The treatment he receive for his GBM brain tumour was based on immunotherapy which he had developed as an effective treatment against Malignant Melanoma. It basically consisted of pre-surgical immunotherapy (aka "neoadjuvant") followed by post-excision immunotherapy with an combination of agents.

As part of the process in the preparation of the vaccine, both the patient's genome and that of the tumour were analysed and this seems to be part of a process to decide what would be the best form of immunotherapy (eg the checkpoint inhibitors anti-PD-1, /PD-L1, /PD-L2, or the monoclonal antibody, anti-CTLA-4 etc.) for treating malignant melanoma.

It is not DCVax-L and is in no way similar to it.